<DOC>
	<DOC>NCT00592527</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to evaluate the blood glucose achieved with insulin detemir as add-on to current oral antidiabetic drug (OAD) treatment in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetes for at least 12 months since diagnosis Insulin naive subjects OAD treatment for at least 4 months with max. two OAD treatments Body mass index below 30.0 kg/m2 HbA1c between 7.011.0% OAD treatment with three or more OADs Secondary diabetes Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator Uncontrolled hypertension Known or suspected allergy to trial product or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>